# Interferon Alfa Therapy Based on Th17 Profile in Membranous Nephropathy

> **NCT05941845** · PHASE2 · UNKNOWN · sponsor: **Centre Hospitalier Universitaire de Nice** · enrollment: 5 (estimated)

## Conditions studied

- Membranous Nephropathy

## Interventions

- **DRUG:** Peginterferon Alfa-2A 180 MCG/ML Injectable Solution

## Key facts

- **NCT ID:** NCT05941845
- **Lead sponsor:** Centre Hospitalier Universitaire de Nice
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-07-24
- **Primary completion:** 2025-01-24
- **Final completion:** 2025-07-24
- **Target enrollment:** 5 (ESTIMATED)
- **Last updated:** 2023-07-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05941845

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05941845, "Interferon Alfa Therapy Based on Th17 Profile in Membranous Nephropathy". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05941845. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*